【摘 要】
：
Object To assess the efficacy and toxicity of icotinib,and to analyze possible factors influencing effectiveness in patients with advanced non-small cell lung cancer (NSCLC).Method The clinical data o
【机 构】
：
Clinical Pharmacy Teaching and Research Section,China Pharmaceutical University,Nanjing 210009,China
【出 处】
：
2014华东胸部肿瘤论坛暨第七届浙江省胸部肿瘤论坛
论文部分内容阅读
Object To assess the efficacy and toxicity of icotinib,and to analyze possible factors influencing effectiveness in patients with advanced non-small cell lung cancer (NSCLC).Method The clinical data of 260 patients with NSCLC assigned to the Jiangsu Cancer Hospital were retrospectively analyzed.Result 256 patients were evaluable for efficacy except 4 patients did not tolerate the side effects to stop taking the medicine.Among the 256 patients,there was no complete response (CR),96 (37.5%) patients with partial response (PR),97 (37.9%) patients with stable disease (SD) and 63(24.6%) patients with progression disease (PD).The overall progression-free survival (PFS) was 7 months.The PFS after first-line treatment, second-line treatment, and third or more than third line treatment were 11 (1 ~ 16.3), 6(0.4~11.3), 5(1 ~ 13.5) months, respectively.Conclusion Icotinib is effective and well safety in patients with advanced non-small cell lung cancer.
其他文献
本文就急性白血病并右顶叶占位进行了研究，患者近期无发热，无头痛、头晕，无视物模糊，无吞咽困难，无意识障碍，无喷射性呕吐，无胸闷、气促，无咳嗽、咳痰，无腹胀、腹痛，精神、睡眠、胃纳可，大小便正常，体重无明显改变，运用骨髓细胞学、胸片、心电图等手段对该患者进行了检查，入院后行腰椎穿刺术，以进一步观察颅内病变性质。
本文就慢性粒细胞性白血病的治疗进行了研究，本例患者采用经典的BU/CY预处理方案，摧毁骨髓及免疫系统，3次植入均告失败，经G-CSF及输血支持治疗6个月自体造血仍未恢复，临床及骨髓象改变符合再生障碍性贫血。此类患者既往除支持治疗外无其它更好办法。首次尝试以体外激活的免疫细胞来调节和改善患者免疫功能，促进造血恢复，取得了较好的疗效，患者在治疗过程中除一过性发热外，无其他不良反应，细胞免疫疗法的具体作
病史摘要:患者,男,66岁,因"双下肢骨痛伴腰痛2年余,加重10天."2013年5月8日入院.患者以双下肢骨痛、双侧踝关节及膝关节肿痛为主要表现,疼痛剧烈时影响行走.体查:T36.5 ℃ P83次/分R20次/分 BP124/65mmHg,全身皮肤黏膜未见皮疹,全身浅表淋巴结未及肿大,胸骨无压痛,心肺未见异常,腹软,全腹无压痛、无反跳痛;四肢关节未见畸形,皮温正常,双下肢无浮肿.
目的 探讨多发性骨髓瘤病程中合并淀粉样变性对预后的判断价值.方法 患者男性,50岁,主因反复恶心、呕吐11月余于2013.10.7入院.初诊时血常规示；WBC：12.49*109/L,Hb：91g/L,PLT：105*109/L；血肌酐874μmol/L,尿蛋白(+),本-周氏蛋白尿(+),游离λ,尿微量蛋白λ链1460mg/L,A1-M266mg/L,B2-M150mg/L,全身扁骨平片未见异常
目的 探讨B细胞慢性淋巴增殖性疾病(不能分类)(B-CLPD-U)的诊断和治疗。方法 报道我科收治的伴复杂染色体异常的B-CLPD-U一例,复习文献对其诊断治疗进行讨论。结果 患者,女,63岁,因"反复头晕、乏力1+年,面色萎黄4天"入院。查体：贫血貌,皮肤、巩膜轻度黄染,浅表淋巴结未触及肿大,心肺未见特殊,肝右肋下未触及,脾左肋下约3cm,质地中等。
目的：分析2008～2010年永康市食管癌发病情况.方法：利用2008～2010年永康市社会保障局医保和农保的医疗资料中新发食管癌病例,以及永康市人民医院就诊的新发病食管癌病人的发病数据,分析性别、年龄别和部位别食管癌的发病特点.结果：2008～2010年永康市恶性肿瘤新发病例4194例,食管癌新发病例127例,占3.03％.食管癌发病率为7.46/10万(男性8.98/10万、女性5.87/10
目的：了解上消化道癌相对高发区人群上消化道癌及癌前病变的分布情况,为早诊早治工作提供依据.方法：在浙江省上消化道癌相对较高发区仙居县和天台县,采取分层整群抽样的方法随机抽取部分自然村40～69岁村民作为筛查对象,采取内镜下碘染色及指示性活检进行筛查,并经病理学诊断确诊.结果：2010～2013年间共筛查9037人次,查出癌症106例,检出率为1.17％,其中早期癌79例,早诊率为74.53％;食管
[Purpose] The aim of this phase Ⅱ study was to determine the efficacy and feasibility of incorporating Endostatin into concurrent chemoradiation (CRT) for unresectable locally advanced non-small cell
Purpose To know phosphatidylinositol-3-kinase catalytic α (PIK3CA) mutation in small cell lung cancer (SCLC).Materials and Methods Reverse transcription polymerase chain reaction (RT-PCR) and direct s
Rhizoma paridis is widely used for cancer therapy because of its potential involvement in the suppression of tumor growth.However, at present there is no clearly explanation for the mechanism of Rhizo